Active TP53, in turn, transcriptionally activates Rgs16 and Lpin1, and most likely additional steatogenic genes in a tissue-specific context, ultimately leading to liver steatosis (Figure 6B). This evidence concerns the gene RGS16 and fatty liver disease.